FDA WARNING LETTER

Dexcom receives FDA warning letter for two U.S. manufacturing facilities

The company did not provide details about how many observations were made at the two sites, but said it does not "expect a material impact" from the letter to its manufacturing capacity or its sales guidance for fiscal year 2025.